CAMBRIDGE, Mass., Nov. 2, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that all four of its applications for the Qualifying Therapeutic Discovery Project Credit (Therapeutic Credit) were approved. The Therapeutic Credit allows biotechnology companies to claim a credit for 50% of their qualified investments in qualifying therapeutic discovery projects for 2009 and 2010.
